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Abstract
Background: Gastrin-releasing peptide receptors [GRPR] are highly over-expressed in multiple cancers and have
been studied as a diagnostic target. Multimeric gastrin-releasing peptides are expected to have enhanced tumor
uptake and affinity for GRPR. In this study, a
64Cu-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid [NOTA]-
monomer and two NOTA-dimers of [D-Tyr
6,bAla
11, Thi
13, Nle
14]bombesin(6-14) ] [BBN(6-14)] were compared.
Methods: Monomeric and dimeric peptides were synthesized on solid phase support and radiolabeled with
64Cu.
NOTA-dimer 1 consists of asymmetrically linked BBN(6-14), while NOTA-dimer 2 has similar spacer between the two
BBN(6-14) ligands and the chelator. In vitro GRPR-binding affinities were determined with competitive binding
assays on PC3 human prostate cancer cells. In vivo stability and biodistribution of radiolabeled compounds were
assessed in Balb/c mice. Cellular uptake and efflux were measured with radiolabeled NOTA-monomer and NOTA-
dimer 2 on PC3 cells for up to 4 h. In vivo biodistribution kinetics were measured in PC3 tumor-bearing Balb/c
nude mice by μ-positron emission tomography [μPET] imaging and confirmed by dissection and counting.
Results: NOTA-monomer, NOTA-dimers 1 and 2 were prepared with purity of 99%. The inhibition constants of the three
BBN peptides were comparable and in the low nanomolar range. All
64Cu-labeled peptides were stable up to 24 h in mouse
plasma and 1 h in vivo.
64Cu/NOTA-dimer 2 featuring a longer spacer between the two BBN(6-14) ligands is a more potent
GRPR-targeting probe than
64Cu/NOTA-dimer 1. PC3 tumor uptake profiles are slightly different for
64Cu/NOTA-monomer
and
64Cu/NOTA-dimer 2; the monomeric BBN-peptide tracer exhibited higher tumor uptake during the first 0.5 h and a fast
renal clearance resulting in higher tumor-to-muscle ratio when compared to
64Cu/NOTA-dimer 2. The latter exhibited higher
tumor-to-blood ratio and was retained longer at the tumor site when compared to
64Cu/NOTA-monomer. Lower ratios of
tumor-to-blood and tumor-to-muscle in blocking experiments showed GRPR-dependant tumor uptake for both tracers.
Conclusion: Both
64Cu/NOTA-monomer and
64Cu/NOTA-dimer 2 are suitable for detecting GRPR-positive prostate
cancer in vivo by PET. Tumor retention was improved in vivo with
64Cu/NOTA-dimer 2 by applying polyvalency
effect and/or statistical rebinding.
Keywords: Bombesin, homo-dimer,
64Cu, PET imaging, gastrin-releasing peptide receptors, PC3 tumor.
Background
Prostate cancer is the most frequently diagnosed cancer
and the second leading cause of cancer-related deaths
for males in the USA. One promising approach in
prostate cancer diagnosis is the utilization of target-spe-
cific radiolabeled peptides for positron emission tomo-
graphy [PET] imaging. Previous researches have shown
that bombesin [BBN] analogs can be used to target gas-
trin-releasing peptide receptors [GRPR] with high affi-
nity and selectivity. Gastrin-releasing peptide [GRP] is a
27-amino acid peptide that displays a wide range of phy-
siological effects, including gastric and pancreatic secre-
tions, nervous system stimulation, smooth muscle
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growth in some malignant cell lines [1,2]. The presence
of GRPR has been documented in small cell lung can-
cers [3], prostate cancers [4,5], breast cancers [6-8] and
others [9]. In prostate cancer, the GRPR expression has
been tied to neoplastic transformation [10], cell migra-
tion [11,12], proliferation [10,13] and invasion capacity
[14-16]. GRPR is overexpressed on 84% of all human
prostate cancers according to a study by Markwalder
and Reubi [5]. These receptors represent an interesting
molecular target for radiolabeled BBN analogs as diag-
nostic or radiotherapeutic applications for prostate can-
cer. BBN, a 14-amino acid-potent GRPR agonist found
in the skin of the fire-bellied toad Bombina bombina,
was first described by Anastasi et al. [17]. BBN is
involved in regulating exocrine secretion, smooth mus-
cle contraction and gastrointestinal hormone release
[18], and it is widely expressed in the central nervous
system [19]. [D-Tyr
6,bAla
11,T h i
13,N l e
14]BBN(6-14)
[BBN(6-14)] is a potent modified GRPR agonist peptide
that binds to GRPR with high affinity [20]. Various BBN
analogs have been labeled with radiometals and used for
PET imaging of GRPR-positive tumors. Schuhmacher et
al. labeled a 1,4,7,10-tetraazacyclododecane-N, N’,N ’’,
N’’’-tretraacetic acid [DOTA]-PEG [polyethylene glycol]
2-BBN(6-14) with
68Ga [21] for PET imaging, while
Chen et al. used DOTA-Lys
3-bombesin with
64Cu [22].
Smith et al. successfully labeled modified BBN(7-14)
analogs with
64Cu for potential use in diagnostic ima-
ging using 1,4,7-triazacyclononane-1,4,7-triacetic acid
[NOTA] or NO2A as chelating agents and obtained
stable compounds [23,24].
To improve peptide-binding affinity, a multivalency
approach has been introduced [25]. Traditionally, this
approach involves the use of peptide homodimers or
homomultimers in which peptide ligands of the same
type are constructed with suitable linkers. The key for
bivalency, binding to two receptors at the same time, is
the distance between the two peptide motifs. The ability
of a dimer peptide to achieve bivalency depends also on
the receptor density [25]. If the receptor density is very
high, the distance between two neighboring receptor
sites will be short, which makes it easier for the dimer
peptide to achieve the bivalency. While GRPR density
on PC3 tumor cells is widely documented in vitro and
in vivo, its expression is heterogeneous making it diffi-
cult to establish an average distance between the recep-
tors [4]. Even if the distance between the two peptide
motifs is not optimal, the local BBN peptide levels may
still be high in the vicinity of GRPR sites once the first
BBN ligand is bound. The detachment of the dual action
ligand from the receptor is more likely to be followed by
re-attachment if there are GRPR binding copies close to
it, resulting in higher receptor affinity for homodimers
and better tumor uptake with longer tumor retention
[26]. Potential benefits of multimeric targeting peptides
are accepted, but many questions concerning the
mechanisms are still to be answered. A few studies on
BBN-based homodimers have been reported with vary-
ing results. Carrithers and Lerner observed modest
improvement in affinity for GRPR with their homodimer
[27], while Gawlak et al. noted no difference in affinity
between their monomer and homodimer [28]. Abiraj et
al. observed higher cellular uptake and retention of their
homodimers radiolabeled with
177Lu on GRPR-over-
expressing PC3 cells [29].
64Cu has mean positron energy similar to that of
18F
and a half-life of 12.7 h permitting PET evaluation of
slow bio-chemical pathways, such as protein and peptide
interactions with cellular targets [30]. Our laboratory
has reported the synthesis and the characterization of
DOTA and NOTA-BBN derivatives and showed that
the NOTA-BBN(6-14) had an inhibition constant [Ki]
value slightly lower than that of the analog DOTA-BBN
(6-14) [31]. NOTA has been radiolabeled efficiently with
64Cu and shown to have higher resistance to transmetal-
lation reactions in vivo as compared to DOTA [23,35].
In the present study, we studied the GRPR affinity, the
cellular uptake and efflux, the in vivo stability and the
biodistribution of radiolabeled NOTA-BBN monomer
and NOTA-BBN homodimers 1 and 2 which differed by
the spacer length between the two peptide ligands (Fig-
u r e1 ) .O u rd e s i g ni sb a s e do nt h eo n l ye x a m p l ea v a i l -
able of radiolabeled BBN-based homodimer from Abiraj
et al. [29]. They used lysine side chain or a 6-aminohex-
anoic acid spacer for their homodimer and obtained
promising in vitro results. We used one and two PEG
spacers between the binding sequences to fine-tune bio-
logical properties of our homodimers. In addition, we
reported a convenient synthetic approach for the pre-
paration of two NOTA-BBN homodimers and their
labeling with
64Cu (Figure 2). μPET imaging on PC3
human prostate carcinomas xenografted in Balb/c nude
mice was also performed to compare the diagnostic
properties of
64Cu/NOTA-BBN homodimers homodi-
mers to those of the
64Cu/NOTA-BBN monomer.
Methods
Materials
All chemicals and solvents (reagent grade) were used as
supplied from the vendors cited below without further
purification, unless otherwise noted. NovaSyn
® TGR
resin and Sieber amide resin were obtained from EDM/
NovaBiochem(Gibbstown, NJ, USA). Fmoc-protected
amino acids and benzotriazol-1-yl-oxytripyrrolidinopho-
sphonium hexafluorophosphate [PyBOP] were obtained
from EMD NovaBiochem
® (Gibbstown, NJ, USA) or
Chem-Impex International Inc. (Wood Dale, IL, USA).
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Page 2 of 151,4,7-Triazacyclononane was obtained from TCI Amer-
ica (Portland, OR, USA). 2-(1H-7-Azabenzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate
[HATU] was purchased from Chem-Impex International
Inc., and 6-Chloro-1-hydroxy-1H-benzotriazole
[ClHOBT] was purchased from ChemPep (Wellington,
FL, USA) and Matrix Innovation (Quebec, QC, CA). 4-
(2-Hydroxyethyl)-1-piperazineethanesulfonic acid
[HEPES], amphothericin B, Ham’s F-12, phosphate-
buffered saline [PBS], trypsin, penicillin, streptomycin
and fetal bovine serum were purchased from Wisent
(St-Bruno, Quebec, Canada). N, N-Diisopropylethyla-
mine [DIEA], thioanisole were obtained from Aldrich
Chemical Company, Inc. (Milwaukee, WI, USA). Bovine
serum albumin [BSA] and bombesin were purchased
from Sigma-Aldrich Company (Saint-Louis, MO, USA).
Acetonitrile [MeCN], dichloromethane [DCM], N, N-
dimetylformamide [DMF] and isopropyl alcohol were
Figure 1 Amino-acid sequences of NOTA-bombesin monomer and dimers with
64Cu.
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Canada).
125I-bombesin was purchased from Perkin
Elmer Life Science Products (Boston, MA, USA). Finally,
T47D human breast cancer and PC3 cell lines were
obtained from American Type Culture Collection (Man-
assas, VA, USA). DMF was dried over 4 Å molecular
sieves at least 1 week to remove trace amount of amine
present in the solvent and filtered before its use.
Peptide Synthesis
We recently reported the synthesis, the characteriza-
tion and the biological activity of NOTA-BBN(6-14)
peptide [31]. The general procedure for the prepara-
tion of NOTA-BBN(6-14) dimers on solid support is
summarized in Figure 2. The south BBN peptide seg-
ment was synthesized on amide Sieber resin by a con-
tinuous flow method on a Pioneer™ Peptide Synthesis
System (PerSeptive Biosystems; Framingham, MA,
USA) using the Fmoc strategy. A two-fold excess of
Fmoc-protected amino acid over available resin substi-
tution sites was used for coupling in amine-free DMF.
Fmoc-protected amino acids were activated for cou-
pling with an equi-molar amount of HATU and two
equivalents of DIEA. Fmoc deprotection was per-
formed in 20% piperidine in DMF and monitored
through absorbance at 364 nm. The resin was washed
three times with DMF, MeOH, DMF, MeOH and
DCM, subsequently. The partially protected peptide-
resin was swelled in 2 mL of DMF and, then, treated
with 3 mL of DMF containing succinic anhydride (10
equivalents) and DIEA (10 equivalents). This coupling
procedure was performed twice (30 min and 1 h). The
resin was washed as described above, and the desired
peptide was cleaved from the support by treatment
with a cocktail of 4% trifluoroacetic acid [TFA] in10
mL DCM at room temperature under mechanical agi-
tation for 3 min. The solution was filtered into a flask
containing 5% Et3N in MeOH. The cleavage step was
repeated 10 times. Combined filtrates containing the
partially protected peptide were evaporated under
reduced pressure to 5% of the volume. Cold water (40
mL) was added to the residue, and the mixture was
cooled with ice to aid the precipitation of the product.
The precipitated peptides were centrifuged at 1,200
rpm for 15 min. The water solution was decanted, and
the white solid was dried under vacuum. Purity of the
crude peptide was verified by high performance liquid
chromatography [HPLC] and, its identity was con-
firmed by API 3000 LC/MS/MS (Applied Biosystems/
MDS SCIEX, Concord, Ontario Canada).
Figure 2 Synthesis scheme for NOTA BBN-based dimers.
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Page 4 of 15The north BBN peptide segment was synthesized on
NovaSyn
® TGR resin and the automated system follow-
ing the procedure described above. After completion of
the BBN fragment, the Fmoc-NH-(PEG)1-CO2Ha n d
Fmoc (ivDde)Lys-OH were coupled manually to the
peptide on resin. The Fmoc-NH-(PEG)1-CO2H( 2 . 5
equivalents) was dissolved in 2 mL of DMF at 0°C,
DIEA (2.5 equivalents) and PyBOP (2.5 equivalents)
were added to the cold solution. After 15 min of stir-
ring, the mixture was added to the partially protected
peptide-resin pre-swelled with DCM and mixed with
ClHOBt (2.5 equivalents) and DIEA (2.5 equivalents),
while mechanical agitation was maintained for 2 h at
room temperature. The resin was washed three times
with DMF, MeOH, DMF, MeOH and DCM, subse-
quently. Fmoc deprotection was performed in 20%
piperidine in DMF during 15 min, and the resin was
washed as described above. For the preparation of the
NOTA-dimer 1, steps 1 and 2 of Figure 2 were not per-
formed. The Fmoc-Lys(ivDde)-OH was dissolved in 2
mL of DMF at 0°C, and HATU (2.5 equivalents) was
added to the cold solution. The mixture was added to
the partially protected peptide-resin pre-swelled with
DCM and DIEA (2.5 equivalents) and, then, mechani-
cally stirred for 1 h. The resin, the Fmoc group and the
last Fmoc-NH-(PEG)1-CO2H were respectively washed,
deprotected and coupled as described above. The result-
ing N-terminal Fmoc was deprotected in 20% piperidine
in DMF for 15 min, and the resin was washed as
described above. The coupling and the Fmoc deprotec-
tion steps were followed by a Kaiser’st e s to nr e s i n ;t h e
reaction between resin and ninhydrin was followed col-
orimetrically whereby free primary amines after Fmoc
deprotection were detected as blue beads, and their
absence as yellow beads. The resin was washed as
described above.
Coupling of the north BBN segment to the south peptide
The solution of HO-Suc-partially protected-BBN(6-14)
was activated with PyBOP (1.5 equivalents), ClHOBt (1.5
equivalents) and DIEA (3 equivalents) in DMF:NMP (1:1
v/v). The pre-activation mixture was stirred for 15 min
and, then, added to the NH2-PEG-Lys(ivDde)-(PEG)-Gly-
BBN-peptide on TGR resin pre-swelled in DMF (2 mL).
The reaction was allowed to proceed for 12 h at room
temperature under mechanical agitation. The coupling
was performed twice with another equivalent of the HO-
Suc-partially protected-BBN(6-14). After the north BBN
segment coupling, the NOTA group was built on solid
phase as described previously by our group [31]. The resin
was washed as described above, and the peptide was
deprotected and cleaved from the support by treatment
with a cocktail of TFA/H2O/thioanisole (92:2:6, v/v/v) for
4 h at room temperature under mechanical agitation to
yield the desired peptide. The resin was removed by filtra-
tion and washed with TFA. Combined filtrates were added
dropwise to cold diethyl ether. For each 1 mL of TFA
solution, 10 mL of diethyl ether was used. The precipitated
peptides were centrifuged at 1,200 rpm for 15 min. The
ether solution was decanted, and the white solid was dis-
solved in water, frozen and lyophilized. The crude peptide
was purified by flash chromatography on a Biotage SP4
system (Biotage, Charlotte, NC, USA) equipped with a C18
column. Purity of the peptides was verified by HPLC, and
their identity was confirmed by API 3000 LC/MS/MS
(Applied Biosystems/MDS SCIEX) and MALDI. Analytical
HPLC was performed on an Agilent 1200 system (Agilent
Technologies, Mississauga, Ontario, L5N 5M4, Canada)
equipped with a Zorbax Eclipse XDB C18 reversed-phase
column (4.6 × 250 mm, 5 μ) and Agilent 1200 series diode
array UV-Vis detector (Agilent Technologies) using a lin-
ear gradient of 0% to 100% acetonitrile in water with 0.1%
TFA over 30 min at a flow rate of 1 mL/min. Following
these methods, NOTA-PEG-BBN(6-14) (denoted as
NOTA-monomer), BBN(6-14)-Suc-PEG-Lys(NOTA)-Gly-
BBN(6-14) (denoted as NOTA-dimer 1) and BBN(6-14)-
Suc-PEG-Lys(NOTA)-PEG-Gly-BBN(6-14) (denoted as
NOTA-dimer 2) were prepared.
Cell culture
The human prostate cancer PC3 cell line was used in
their 8th to 12th passage after receipt and was cultured
in Ham’s F12 medium supplemented with 2.5 mM glu-
tamin, 100 U/mL penicillin, 100 μg/mL streptomycin,
100 ng/mL amphothericin B and 10% fetal bovine
serum. Cells were grown in 5% CO2 in air at 37°C; the
medium was changed three times per week.
Competitive binding assays
Competition assays were performed in 24-well plates
using PC3 cells. The cells were cultured until near con-
fluence, and the medium was replaced by 400 μLo f
reaction medium (RPMI complemented with 2 mg/mL
BSA, 4.8 mg/mL HEPES, 1 U/mL penicillin G and 1 μg/
mL streptomycin). For the assay, equal volumes of
radioactive and non-radioactive ligands were added. The
concentration of [
125I-Tyr
4]bombesin (74 TBq/mmol;
Perkin Elmer Life Science Products, Boston, MA, USA)
was 10
-12 M. Increasing concentrations (10
-6 to 10
-14)o f
the GRPR ligand were added. The plates were incubated
for 40 min at 37°C with agitation. After the incubation,
the reaction medium was removed, and the cells were
washed three times with PBS at room temperature. The
cells were harvested and counted in a gamma counter
(Cobra II auto-gamma counter, Packard, MN, USA).
Experiments were realized three times in triplicate. Data
were analyzed with GraphPad Prism 5 Software (Graph-
Pad Software, San Diego, CA, USA) to determine the
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Pursoff’s formula [32]. The Kd value for [
125I-Tyr
4]bom-
besin has been determined from experiments done
under similar conditions and is 1.5 × 10
-10 M.
Peptide radiolabeling with
64Cu
Our cyclotron facility provides
64Cu isotope on a routine
basis for research purposes using a target system devel-
oped in collaboration with Advanced Cyclotron Systems
Inc. (ACSI, Richmond, British Columbia, Canada).
64Cu
was prepared on an EBCO TR-19 cyclotron (EBCO
Technologies, Vancouver, Canada) by the
64Ni(p, n)
64Cu
nuclear reaction using an enriched
64Ni target electro-
plated on a rhodium disk [33]. [
64Cu]CuCl2 was recov-
ered from the target following the procedure of
McCarthy et al. [34] and converted to [
64Cu]copper[II]
acetate by dissolving the [
64Cu]CuCl2 in ammonium
acetate (0.1 M; pH 5.5). Peptides were labeled with
64Cu
following conditions optimized in our laboratory. Briefly,
peptides (5 μg) were dissolved in a 0.1 M ammonium
acetate buffer at pH 5.5 with [
64Cu]Cu(OAc)2 (8 to 10
mCi, 296 to 370 MBq) in a total volume of 250 to 300
μL, and then, the resulting solution was incubated at
100°C for 10 min. The labeled product was purified by
HPLC using a C-18 column and a radio-detector. The
amount of radiolabeled peptide was determined by the
peak area of the tracer in the UV-chromatogram com-
pared to the UV peak area of the standard unlabelled
peptide (Figure 3). In all cases, starting materials and
radiolabeled peptides were separable. The peptide frac-
tion was collected, evaporated and counted in a Capin-
tec radioisotope calibrator (Capintec, Inc., NJ, USA) to
calculate the specific activity of the product. Since
64Cu-
labeled NOTA-dimer 1 and NOTA-dimer 2 were poorly
soluble in physiological media, a mixture of DMF-PBS
(10/90 v/v) was used to solubilize the peptides.
In vivo stability studies
Plasma and in vivo stability studies were realized as pre-
viously described by our group [35]. Briefly, after
peptide reconstitution, studies were carried out by incu-
bating the tracers in mouse plasma for a period of 24 h
and by injecting around 15 to 25 MBq (400 to 650 μCi;
100 μL) of
64Cu/peptide to female Balb/c mice; 3 mice
per peptide. After 24 h, a portion of the incubation mix-
tures in plasma or blood samples taken from the back
paw were quenched with equal amounts of MeCN,
chilled (4°C) and centrifuged, and the supernatant was
assayed by HPLC. The stability was also determined by
radio-TLC directly from plasma and blood samples
without further handling; free
64Cu and purified radiola-
beled peptides were used as standards. The radio-TLCs
were eluted on C-18-coated plastic sheets with 0.1 M
sodium citrate buffer at pH 5.5 using an instant imager
system for the radio-detection.
Biodistribution studies in Balb/c mice
To determine the in vivo GRPR-targeting efficacy of
labeled peptides, biodistribution of female Balb/c mice
were realized with a minimum of 4 mice for each condi-
tion. Briefly, mice were injected with 370 to 740 kBq (10
to 20 μCi; 100 μL) of either
64Cu/NOTA-monomer,
64Cu/NOTA-dimer 1 or
64Cu/NOTA-dimer 2 via the
caudal vein. The animals were sacrificed with CO2 at 30
min post-injection [p.i.]. Organs of interest were then
collected, weighed and measured in a gamma counter.
The results were expressed as percentage of the injected
dose per gram of tissue [%ID/g].
Cellular uptake and efflux
Cellular uptake and efflux studies were realized three
times in triplicate on PC3 cells in presence of NOTA-
monomer and NOTA-dimer 2 radiolabeled with
64Cu.
First, PC3 cells were seeded in 12-wells plates at a den-
sity of 2 × 10
5 cells per well 48 h prior to the experi-
ment. Before the experiment, the cells were washed
three times with PBS, then 950 μL of culture medium
was added. For cellular uptake, PC3 cells were incubated
15, 30, 60, 120 and 240 min with 37 kBq (1 μCi; 50 μL)
of radiolabeled peptide per well at 37°C with agitation.
Figure 3 Representative radio-HPLCs for the purification of
64Cu/NOTA-monomer. Ultraviolet [UV] profile of the starting material (223 nm;
absorbance units, black line), UV profile of the purified
64Cu/NOTA-monomer (223 nm, absorbance units, blue line), radioactive detection of the
purified
64Cu/NOTA-monomer (mV, red line).
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removed, and the cells were washed three times with
PBS. The cells were harvested and counted in a gamma
counter. The results were expressed as percentage of
added dose retained per 10
5 cells (%AD/10
5 cells). For
efflux studies, plated-PC3 cells were incubated 1 h with
37 kBq (1 μCi; 50 μL) of radiolabeled peptide. Then, the
cells were washed with PBS and fresh medium was
added. After 0, 15, 30, 60, 120 and 240 min, the cells
were washed thrice with PBS. Finally, the cells were har-
vested and counted in a gamma counter. The results
were expressed as percentage of activity retained by cells
relative to baseline at 0 min.
PET imaging
PET scans were performed using a LabPET8 (Gamma
Medica-IDEAS Inc., Sherbrooke, Quebec, Canada) small-
animal scanner with a field of view of 7.5 cm. Female
Balb/c nude mice were implanted with 10
7 PC3 prostate
cancer cells. Cells were injected in 150 μLo fM a t r i g e l
(BD Biosciences, Mississauga, Ontario, Canada) and PBS
(2:1). Tumors were given 3 weeks to grow to the size of 5
mm in diameter. For μPET studies, PC3 xenografted
female Balb/c nude mice were injected with 3.7 to 7.4
MBq (100 to 200 μCi; 100 μL) of
64Cu/NOTA-monomer
or
64Cu/NOTA-dimer 2 via the caudal vein under isoflur-
ane anesthesia with a minimum of 3 mice for each tracer.
Each animal had a 2-h dynamic scan from the injection.
T h ei m a g e sw e r er e c o n s t r u c t e db ya2 - d i m e n s i o n a l
MLEM algorithm implemented on an analytically derived
system matrix [36]. Region of interest [ROI] was traced
for tumor, liver, kidney and muscle. The activity con-
tained in each organ was measured at multiple time
points, resulting in time-activity curves.
Biodistribution studies in PC3 tumor-bearing Balb/c nude
mice
Tumor-bearing Balb/c nude mice were injected with 370
to 740 kBq (10 to 20 μCi; 100 μL) of
64Cu/NOTA-
monomer and
64Cu/NOTA-dimer 2 via the caudal vein
and sacrificed with CO2 at different periods of time
after injection. Organs of interest were then collected
and weighed. -Radioactivity was measured in a gamma
counter. The blocking experiments were realized by co-
injecting 0.1 μmol of non-radiolabeled peptide. The
results were expressed as %ID/g with a minimum of 3
mice for each condition.
Results
Peptide synthesis
NOTA-monomer, NOTA-dimers 1 and 2 were prepared
with overall yields of 38, 28 and 31%, respectively, based
on the substitution rate of the resin determined photo-
metrically from the amount of Fmoc chromophore
released upon treatment of the resin with piperidine/
DMF. According to analytical HPLC, the purity was 99%
for all peptides as reported in Table 1. The purity of the
crude south BBN peptide segment was 84%. The peptide
was used for the coupling without further purification;
the partially protected peptide degrades when purified
by HPLC. All measured peptide masses are in agree-
ment with the calculated mass values (Table 1).
Competitive binding assays
All three peptide conjugates inhibited the binding of
[
125I-Tyr
4]bombesin to GRPR of PC3 cells in a concen-
tration-dependant manner. The Ki values for NOTA-
monomer, NOTA-dimer 1 and NOTA-dimer 2 were
2.51 ± 1.54, 2.00 ± 1.59 and 1.76 ± 1.30 nM, respectively
(see Table 1). Natural bombesin was used as a standard,
and a Ki value of 0.59 ± 0.32 nM was obtained under
the same conditions (Table 1). No significant difference
was observed between the different compounds in terms
of GRPR affinity.
Peptide radiolabeling with
64Cu, purification and in vivo
stability
All NOTA-peptides were successfully radiolabeled with
64Cu with yields not decay corrected greater than 95%
(Table 1). The specific activities measured were 74 to 93
TBq/mmol (2,000 to 2,500 Ci/mmol) for NOTA-mono-
mer, and 93 to 130 TBq/mmol (2,500 to 3,500 Ci/mmol)
for
64Cu/NOTA-dimers 1 and 2. Figure 4 shows radio-
HPLC chromatograms of
64Cu/NOTA-monomer and
64Cu/NOTA-dimer 2. The two tracers were stable in
m o u s ep l a s m ao v e r2 4ha n din vivo over 1 h (Figure 4a,
b). The amount of radiolabeled peptide in mouse blood
was not sufficient after 24 h to run a radio-HPLC. Instead,
stability results were performed by radio-TLC using free
64Cu and purified radiolabeled peptides as standards. Fig-
ure 5 shows radio-TLC chromatograms of
64Cu/NOTA-
monomer and
64Cu/NOTA-dimer 2 at various time points
in mouse plasma and in vivo. The absence of free
64Cu in
vivo 24 h p.i. confirmed that
64Cu/NOTA complexes of
the monomer and the dimer 2 are stable (Figure 5). No
metabolites were found under all conditions when the sta-
bility was followed by radio-TLC.
Biodistribution in Balb/c mice
The GRPR-targeting in vivo efficacy of
64Cu-labeled
peptides was first tested by biodistribution in female
Balb/c mice 30 min p.i. using the pancreas, a GRPR-rich
tissue, as a target for specific receptor-mediated accu-
mulation. We also determined the biodistribution pro-
files of our peptides (Figure 6). Both dimers present
higher liver, spleen, lung and kidney uptake. Pancreas
uptake were respectively 18.4 ± 2.9, 15.6 ± 2.0 and 57 ±
16%ID/g for NOTA-monomer, NOTA-dimer 1 and
Fournier et al. EJNMMI Research 2012, 2:8
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Page 7 of 15NOTA-dimer 2. NOTA-dimer 2 exhibits a 3.6-fold
higher pancreas uptake than NOTA-monomer and
NOTA-dimer 1.
Cellular uptake and efflux
To further investigate the polymeric effect observed, we
studied cellular uptake and efflux of NOTA-monomer
and NOTA-dimer 2 on PC3 cells. The expected advan-
tages of multimeric compound are a higher uptake and
retention of the peptide on GRPR-expressing tumor
cells. Results are presented in Figure 7. For uptake stu-
dies, a significantly higher cellular uptake is observed for
the labeled NOTA-monomer at multiple time points (p
< 0.05). However, efflux studies demonstrate a higher
retention of the labeled NOTA-dimer 2 when compared
to NOTA-monomer at 1, 2 and 4 h (p < 0.05).
PET imaging
Representative decay-corrected transaxial images at 30,
6 0a n d1 2 0m i na f t e ri n j e c t i o na r es h o w ni nF i g u r e8 .
White arrows indicate the location of the PC3 tumors
which were clearly visible at all times with both radiola-
beled tracers. From these images, it is evident that the
monomer is eliminated from non-target tissue faster than
the dimer. Figure 9 presents time-activity curves of liver,
kidney, muscle and PC3 tumor with both tracers for the
2-h dynamic scan. From these results, no significant dif-
ference was observed between both tracers in terms of
muscle accumulation. However,
64Cu/NOTA-dimer 2
exhibits higher liver (p <0 . 0 5 )a n dk i d n e y( p <0 . 0 5 )
uptake than the
64Cu/NOTA-monomer. PC3 tumor
uptake profiles are slightly different for both tracers dur-
ing the first hour p.i.; the monomer exhibits higher
uptake during the first half-hour that decreases rapidly to
be lower for the next 30 min when compared to NOTA-
dimer 2. After 1 h, the dimer exhibited higher retention
at the tumor site, in accordance with the higher retention
of the NOTA-dimer 2 in cell efflux studies (Figure 7).
Biodistribution in Balb/c nude mice
In order to validate the results obtained by PET ima-
ging, biodistribution in PC3 tumor-bearing female Balb/
Table 1 Analytical data for NOTA-BBN(6-14) monomer and dimmers
Peptide [M]
+ Yield Purity
b Ki
c Labeling
Calcd Found
a (%) (%) (nM) yield
d (%)
Bombesin 0.59 ± 0.32
NOTA-monomer 1,570 1,571 38 99 2.51 ± 1.54
e >9 5
South BBN peptide segment 1,879 1,880 84
f
NOTA-dimer 1 2,976 2,976 28 99 2.00 ± 1.59 > 95
NOTA-dimer 2 3,122 3,122 31 99 1.76 ± 1.30 > 95
aMass values were obtained by MALDI TOF mass spectroscopy or LC/MS/MS.
bPurity was determined by HPLC analysis.
cAffinities for GRPR were determined with
[
125I-Tyr
4]bombesin in PC3 human prostate cancer cell line.
dLabeling yield (not decay-corrected) was determined by radio-HPLC analysis based on
64Cu starting
activity.
eSimilar Ki values were obtained for the free chelate (1.30 ± 0.74) and the ‘cold’ Cu/NOTA-monomer (1.60 ± 0.59) when tested in triplicate in human
breast cancer T47D cells.
fHPLC yield of the crude peptide. NOTA, 1,4,7-triazacyclononane-1,4,7-triacetic acid; Ki, inhibition constant.
Figure 4 Representative HPLC radiometric profiles of stability studies.( a)
64Cu/NOTA-monomer and (b)
64C u / N O T A - d i m e r2a f t e rf i n a l
formulation (black line), after incubation in mouse plasma (24 h, red line) and after 1 h in vivo (blue line).
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Page 8 of 15cn u d em i c ew a sr e a l i z e df o r
64Cu/NOTA-monomer at
0.5 h and
64Cu/NOTA-dimer 2 at 0.5 h and 2 h. Results
a r ep r e s e n t e di nT a b l e2 .
64Cu/NOTA-monomer dis-
played fast blood clearance with 1.35 ± 0.47%ID/g
remaining in the blood at 0.5 h after injection. Blocking
studies revealed an increased uptake of
64Cu/NOTA-
monomer in all organs except pancreas. Ratios of
tumor-to-blood and the tumor-to-muscle between
unblocked and blocked mice decreased for this tracer.
The uptake in the blood, kidney, liver, spleen, lungs and
tumor is higher for
64Cu/NOTA-dimer 2. A modest
decreased uptake was observed at the PC3 tumor site
for the dimer 2 with co-injection of 0.1 μmol of non-
radiolabeled peptide, but the tumor-to-blood ratio
between unblocked and blocked mice significantly
diminished. The uptake in the pancreas, which is known
to express GRPR, was high and specific for the dimer 2.
Surprisingly, a significant reduced uptake was also
observed in the liver.
Discussion
In this study, we investigated the potential benefits of
dimeric BBN-based peptide radio-tracers for GRPR-
mediated prostate cancer PET imaging. Multimeric
compounds are expected to have higher affinity, when
targeting receptor at the surface of tumor cells, and a
higher tumor uptake and retention than their mono-
meric counterparts [26]. The binding affinity for GRPR
on PC3 cells of NOTA-monomer, NOTA-dimer 1 and
NOTA-dimer 2 was similar in the low nanomolar range.
The incorporation of the NOTA chelator seems to have
a minimal effect on the receptor binding affinity of the
peptides [31]. Competitive binding assays demonstrated
no advantage in terms of receptor affinity through
Figure 5 Representative radio-TLC of stability studies.( a)
64Cu/NOTA-monomer and (b)
64Cu/NOTA-dimer 2 after final formulation (green
line), 24 h incubation in mouse plasma (red line), 1 h in vivo (blue line), 24 h in vivo (purple line) and free
64Cu (black line).
Figure 6 Biodistributions of
64Cu-labeled NOTA-monomer, NOTA-dimer 1 and NOTA-dimer 2. Biodistributions are at 0.5 h post-injection in
Balb/c female mice (four mice/group). Results are presented as mean %ID/g ± SD. The p value refers to the difference between NOTA-dimer 1
(black filled square) and NOTA-monomer (empty square) or NOTA-dimer 2 (stripped filled square) and NOTA-monomer. Asterisk, p < 0.05.
Fournier et al. EJNMMI Research 2012, 2:8
http://www.ejnmmires.com/content/2/1/8
Page 9 of 15dimerization. Previous studies also suggested that homo-
dimers show no or modest improvement in affinity for
GRPR [27,28].
The specific activities of the dimers were slightly
higher than that of the monomer when calculated on a
molar basis. Although the amount of peptide conjugate
was kept constant for the labeling, i.e. 5 μg, the quantity
of radioactivity varied in each case, explaining the
observed variations in specific activity.
64Cu/NOTA
monomer and
64Cu/NOTA dimer 2 are stable after 24-h
incubation in mouse plasma and 1 h in vivo as no trace
of free
64Cu or metabolite was detected by radio-HPLC
(Figure 4). Although
64Cu/NOTA complexes of the
monomer and the dimer 2 are stable over 24 h in vivo
(Figure 5), the stability of the peptide itself cannot be
established by radio-TLC because the peptide separation
from its potential metabolites may be extremely difficult
using this method. The biodistribution in female Balb/c
mice demonstrated that our monomeric and dimeric
peptides have different biodistribution profiles (Figure
6). Both dimers presented slightly higher blood retention
and a significantly increased uptake in the spleen, lungs,
kidney and liver as compared to the monomer. These
results appear to correlate to a higher molecular weight
rather than GRPR-mediated polyvalency effect since
none of these organs express high level of GRPR. The
same observation was reported by Liu while testing their
dimer and tetramer of RGD [37]. Higher uptake in liver
for both dimers seems to indicate a different elimination
pathway and kinetics. The liver is an important organ in
Figure 7 Cellular uptake (A) and efflux (B) of
64Cu-labeled NOTA-monomer and NOTA-dimer 2. NOTA-monomer, filled circle; NOTA-dimer
2, filled square. Cellular uptake and efflux on PC3 cells (n = 3).
Figure 8 Decay-corrected transaxial micro-PET images. Images of PC3 tumor-bearing mice at 30, 60 and 120 minutes post-injection of
64Cu/
NOTA-monomer or
64Cu/NOTA-dimer 2.
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Page 10 of 15the metabolism of copper. However, in vivo stability stu-
dies indicated absence of free
64Cu in the blood circula-
tion at all the time points studied (Figure 5),
demonstrating that the observed liver uptake is due to
hepatobiliary excretion of the dimers. Higher uptake in
the kidneys for both dimers can be explained by the
higher molecular weight since larger molecules are more
slowly excreted, but also, under physiological conditions,
our dimers are more positively charged than the mono-
mer. Positively charged molecules are known to be
more retained in the kidneys than neutral molecule [38]
which could also explain our results. Labeled NOTA-
dimer 2 exhibited a 3.6-fold higher pancreas uptake
compared to NOTA-monomer or NOTA-dimer 1 in
Balb/c mice. This augmentation cannot be explained by
the molecular weight difference. Therefore, this higher
uptake could be associated to polymeric effect. We
further investigated this effect on PC3 cells in vitro and
in vivo with NOTA-monomer and NOTA-dimer 2.
Since NOTA-dimer 1 did not present any advantage
over the two other tracers, we stopped its further
development.
During in vitro experiments,
64Cu/NOTA-dimer 2
exhibited lower cellular uptake but higher tumor reten-
tion on PC3 when compared to
64Cu/NOTA-monomer.
The lower cellular uptake could reflect differences in
biological activities between the two peptides. Our efflux
experiments supported the multimeric effect:
64Cu/
NOTA-dimer 2 was retained by PC3 cells longer than
64Cu/NOTA-monomer in the same conditions.
PET imaging in PC3 tumor-bearing mice was used to
compare the pharmacokinetics and distribution of the
monomeric and the dimeric BBN. Dynamic PET was
used to obtain time-activity curves describing the activ-
ity profile of the tracer for each ROI as a function of
time. Time-activity curves for liver, kidney, muscle and
Figure 9 PET-derived time-activity curves. Liver, kidney, muscle and PC3 tumor of tumor-bearing mice injected with
64Cu/NOTA-monomer
(filled circle) or
64Cu/NOTA-dimer 2 (filled square).
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64Cu/NOTA-monomer and
64Cu/NOTA-
dimer 2 showed that liver and kidney uptake was higher
at all times for the dimer, while muscle uptake was simi-
lar for both tracers. These results correspond to the pat-
tern observed in the biodistribution studies. Results
from cellular uptake studies predicted higher tumor
uptake for
64Cu/NOTA-monomer. In fact, PC3 tumor
uptake was higher for
64Cu/NOTA-monomer for the
first 30 min post-injection. Afterwards, the tumor
uptake of the dimer was significantly higher than the
monomer. This can be explained by the slower tumor
washout of the dimer. The longer retention of the dimer
by PC3 cells observed in the efflux studies is also
observed in vivo. Blocking studies by biodistribution in
PC3 tumor-bearing mice were realized to validate the
results obtained by PET imaging, confirming the GRPR-
mediated uptake of the tracer. After co-injection of the
non-radiolabeled peptide, the radioactivity level of
64Cu/
NOTA-monomer slightly decreased in the pancreas.
Surprisingly, an important increase of
64Cu/NOTA-
monomer in all other organs was noticed by co-injection
of the non-radiolabeled peptide. In this study, 0.1 μmol
of non-radiolabeled peptide were co-administered intra-
venously with radiotracer injection, which apparently led
to serious damage to the kidney functions and
significant inhibition of blood clearance of the radiotra-
cer, as suggested by a 9-fold increase in the blood radio-
tracer level and a more than 7-fold increase in the
kidney levels over animals not receiving the non-radiola-
beled peptide. Therefore, the absence of any blocking
effect of the non-radiolabeled peptide in the tumor and
other organs may be explained by interference from an
increased influx of the radiotracer from the blood. At 1
h after the injection of
64Cu/NOTA-monomer, the
radiotracer was still in the form of its parent in the
blood suggesting that the increased uptake of the tracer
may not be related to the uptake of metabolites for the
blocking experiments. Meanwhile, lower tumor-to-blood
ratio of 0.38 ± 0.01 and tumor-to-muscle ratio of 1.59 ±
0.44 were obtained 0.5 h p.i for blocked
64Cu/NOTA-
monomer, with 1.49 ± 0.41 and 7.42 ± 0.41 for the
unblocking experiments respectively (p <0 . 0 5 ,T a b l e2 ) ,
showing that the tumor localization of
64Cu/NOTA-
monomer was a result of the GRPR. For dimer 2, the
uptake in blood, kidney, spleen and muscle is non-speci-
fic since no difference is noted by co-injection of the
non-radiolabeled peptide. The co-injection of the non-
radiolabeled peptide significantly reduced the pancreas
uptake from 13.35 ± 7.38 to 1.43 ± 0.61%ID/g (p < 0.05,
T a b l e2 ) .S i n c eG R P R sa r eh i g h l ye x p r e s si nt h i so r g a n ,
Table 2 Biodistribution and tumor to non-target organ ratios for
64Cu/NOTA-monomer and
64Cu/NOTA-dimer 2
Organ
64Cu/NOTA-monomer
64Cu/NOTA-dimer 2
30 min 30 min 120 min
Unblocked Blocked
a Unblocked Unblocked Blocked
a
Blood 1.35 ± 0.47 12.72 ± 3.42 3.13 ± 0.67 1.34 ± 0.15 3.32 ± 2.78
Plasma 2.48 ± 0.63 21.69 ± 6.16 5.27 ± 1.27 2.45 ± 0.27 6.14 ± 4.89
Adrenal 4.29 ± 1.13 16.57 ± 0.37 9.23 ± 5.01 11.56 ± 4.91 3.63 ± 2.43
Fat 0.65 ± 0.54 3.22 ± 4.29 1.86 ± 0.81 0.68 ± 0.61 3.46 ± 2.74
Kidney 10.42 ± 1.29 75.13 ± 36.20 17.02 ± 6.24 26.37 ± 8.13 23.00 ± 5.37
Spleen 1.63 ± 1.82 3.29 ± 0.16 5.31 ± 1.43 5.50 ± 2.61 3.31 ± 0.95
Pancreas 5.10 ± 2.50 4.57 ± 2.65 4.60 ± 0.57 13.35 ± 7.38 1.43 ± 0.61
b
Liver 5.38 ± 8.12 8.12 ± 0.70 41.79 ± 5.58 23.11 ± 2.36 12.20 ± 2.78
b
Heart 1.05 ± 0.91 4.65 ± 0.33 4.42 ± 1.59 2.68 ± 0.13 1.58 ± 0.80
Lungs 1.77 ± 1.28 14.26 ± 1.58 7.22 ± 2.73 5.07 ± 1.58 34.42 ± 23.31
Muscle 0.40 ± 0.33 3.45 ± 2.06 1.59 ± 1.16 1.13 ± 0.62 1.41 ± 0.98
Bone 0.43 ± 0.46 1.52 ± 0.58 0.78 ± 0.21 0.83 ± 0.19 1.15 ± 0.44
Brain 0.08 ± 0.07 0.63 ± 0.09 0.38 ± 0.06 0.22 ± 0.05 0.16 ± 0.09
Tumor 1.79 ± 0.46 4.82 ± 0.91 3.95 ± 0.26 6.28 ± 2.87 3.25 ± 1.15
Tumor/blood 1.49 ± 0.41 0.38 ± 0.01
b 1.39 ± 0.30 4.09 ± 1.79 1.04 ± 0.60
b
Tumor/muscle 7.42 ± 3.17 1.59 ± 0.44
b 3.95 ± 1.98 4.46 ± 1.86 2.31 ± 1.46
Tumor/liver 2.07 ± 1.13 0.60 ± 0.13 0.10 ± 0.01 0.22 ± 0.07 0.24 ± 0.09
Tumor/kidney 0.17 ± 0.04 0.07 ± 0.01
b 0.28 ± 0.09 0.22 ± 0.11 0.12 ± 0.03
Tumor/pancreas 0.44 ± 0.17 1.18 ± 0.32
b 0.89 ± 0.11 0.36 ± 0.09 1.80 ± 0.39
b
Biodistribution and ratios are at 30 and 120 min post-injection.
aBlocked by injecting 0.1 μmol of non-radiolabeled peptide together with the radiopeptide.
bCo-
injection significantly lowered the uptake of the same organ for the corresponding tracer (p < 0.05).
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64Cu/NOTA-
dimer 2 is GRPR-mediated. The liver uptake of
64Cu/
NOTA-dimer 2 was also reduced by co-injection of
unlabeled peptide (p < 0.05). Since GRPR expression in
the liver is very low, it is likely that diminution of liver
accumulation may reflect saturation of the hepatobiliary
elimination pathway by the non-radiolabeled peptide.
PC3 tumor uptake of
64Cu/NOTA-dimer 2 was mod-
estly lowered from 6.28 ± 2.87%ID/g to 3.25 ± 1.15%ID/
g following the co-injection of the non-labeled peptide,
again, indicating a GRPR dependant response.
To demonstrate that the higher tumor retention of
64Cu/NOTA-dimer 2 observed in vivo is not only due to
higher molecular weight, we compared the tumor-to-
non-target tissue ratio of radiolabeled NOTA-monomer
and NOTA-dimer 2. If tumor uptake was only due to
size difference among the monomer and the dimer, then
muscle uptake would have increased accordingly, result-
ing in similar ratios of tumor-to-blood and tumor-to-
muscle for both tracers. Results indicate that the
64Cu/
NOTA-monomer offers the highest tumor-to-muscle
ratio during the course of our study (Table 2).
64Cu/
NOTA-dimer 2 exhibits higher tumor-to-blood ratio
after 2 h and is also retained longer at the tumor site. In
addition, this tracer displays lower tumor-to-liver ratio
and similar ratios of tumor-to-kidney and tumor-to-pan-
creas than the NOTA-monomer at all time points.
These ratios are modulated by the different elimination
pathway and kinetics of both tracers.
Multimeric compounds could have enhanced affinity
due to statistical rebinding or simultaneous binding to
receptors. All peptides in the current research feature
only short linkers, limiting the possibility of multiple
binding to targets simultaneously. Therefore, statistical
rebinding seems to be the major factor explaining the
results observed at the pancreas for the dimer 2. The
receptor binding of one BBN(6-14) unit will significantly
enhance the local concentration of the other BBN(6-14)
unit in the vicinity of the receptor which might facilitate
further binding. However, statistical rebinding is depen-
dent on the density of receptor present at the surface of
the cell. GRPRs are characterized by the presence of
high and low affinity states to agonist depending on the
coupling of guanine nucleotide (GDP or GTP) on the
G-protein [39]. Therefore, available receptors that could
bind with our peptides at the tumor are likely even
lower than expected. In fact, we observed significantly
higher uptake in mouse pancreas, which has a very high
d e n s i t yo fG R P R ,b u tn od i f f e r e n c ei nu p t a k ef o rP C 3
tumors that have a lower GRPR density [1]. This differ-
ence in receptor densities might be a factor reducing
the efficacy of our dimer. Longer spacers in the dimer
might allow bivalency, implying that both BBN(6-14)
units can bind simultaneously to GRPR. However, it is
important to note that tumor retention did not seem to
be altered by lower receptor densities. It is possible that,
in the case of the dimeric tracers, different mechanisms
are involved in tumor uptake and retention. Overall, our
data show that
64Cu/NOTA-dimer 2 presents similar
affinity for GRPR and PC3 uptake in vivo, greater tumor
retention in vitro and in vivo but also higher uptake in
the liver and kidney when compared to
64Cu/NOTA-
monomer.
Conclusions
Monomeric and dimeric BBN(6-14) peptides have been
successfully synthesized and labeled with
64Cu as poten-
tial tracers for prostate cancer PET imaging. In this
study, we present (to our knowledge, for the first time)
in vivo characterization of radiolabeled dimeric BBN-
based peptides. Both
64Cu/NOTA-monomer and
64Cu/
NOTA-dimer 2 are suitable for detecting GRPR-positive
prostate cancer in vivo by PET. Tumor retention was
improved in vivo with
64Cu/NOTA-dimer 2 by applying
polyvalency effect and/or statistical rebinding. Our study
is the first step in developing effective dimeric BBN-
based tracers in prostate cancer PET imaging.
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